Selective small-molecule inhibitors of BCL-XL may enhance the efficacy of MLN8237(an Aurora kinase inhibitor) and other targeted chemotherapeutic agents in medulloblastoma and pediatric glioblastoma cells [43]. This evidence concerns the gene BCL2L1 and medulloblastoma.